Navigation Links
Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
Date:4/4/2011

NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced additional data that showed that overweight and obese patients treated with Contrave® (naltrexone sustained release (SR)/bupropion SR) maintained normal 24-hour circadian patterns over one year of treatment.  These data were from the ambulatory blood pressure monitoring (ABPM) sub-study of the COR-II trial that also showed weight loss and improvements in markers of cardiometabolic risk.  Data were presented at the 60th Annual Scientific Session of the American College of Cardiology (ACC) taking place in New Orleans.

"The observation that patients in this sub-study maintained normal circadian variation of blood pressure may be particularly relevant since a loss of the nocturnal lowering in blood pressure may predict a poor cardiovascular outcome," said Jorge Plutzky, M.D., Director of the Vascular Disease Prevention Program at Brigham and Women's Hospital.

Additional results showed Week 52 weight loss of 7.5% for subjects in the sub-study on Contrave as compared to 2.5% for subjects on placebo (P<0.001) and improvements, at Week 56, in waist circumference (-7.5cm vs. -2.3 cm; P<0.001), hs-CRP (-40.7% vs. -2.4%; P<0.01) and HDL-C (+4.4mg/dL vs. -0.6mg/dL; P<0.01) based on LOCF analyses.  

Study Design

The COR-II ABPM sub-study enrolled 182 of the 1496 subjects from the main trial, at nine U.S. sites.  Monitoring of ambulatory blood pressure in the sub-study was initiated prior to the intake of study drug and other morning medications and completed approximately 24-hours later at three time points during the study: baseline, Week 24 and Week 52. COR-II is one of the four Phase 3 trials supporting Orexigen's New Drug Application for Contrave.

About the Contrave Clinical Development Program


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... - New Progression-Free Survival Data Support Picoplatin ... for Metastatic Castration-Resistant Prostate Cancer -- Results ... of Clinical Oncology,s 2009 Genitourinary Cancers Symposium ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ...
... China, Feb. 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... focused on researching,developing, manufacturing and marketing biopharmaceutical products, ... the fourth quarter and,full year ended December 31, ... 11, 2009. , Following ...
... and Sunflower Oils drive better restaurant menu optionsINDIANAPOLIS, Feb. ... significant milestone in North America with the reduction of ... fats over the past three years. Since the market ... by Dow AgroSciences, have replaced more than 340 million ...
Cached Biology Technology:Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 2Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 3Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 4Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 53SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... a trip to Asia to coordinate with allies ... officials at the Office of Naval Research (ONR) ... (APTEP) as an example of strong and growing ... in the region. , The APTEP program, centered ... supports the development of alternative energy technologies. It ...
(Date:4/22/2014)... how communities can protect themselves from worsening storms. ... New England and the Midwest providing practical and ... goal is to help communities begin the steps ... of Syntectic International, Portland, OR. "It,s important because ... beyond feeling paralyzed from the lack of local ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... staff scientist at Carnegie,s Department of Embryology, has ... American Academy of Microbiology. Fellows are annually elected ... their records of scientific achievement and original contributions ... single-celled yeast Saccharomyces cerevisiae , Koshland has ...
... bomb plot was uncovered in London in August 2006, ... (S&T) looked to to find ways to not only ... to figure out what those liquids are. Now, S&T-sponsored ... possible solution. They have successfully tested a liquid ...
... CSC (NYSE: CSC ) announced today that ... Operations and Support Services Unrestricted contract by the Department ... indefinite-delivery/indefinite-quantity (IDIQ) contract covers a broad range of services, ... of BTF business and program units. The contract has ...
Cached Biology News:Carnegie's Doug Koshland elected Fellow of the American Academy of Microbiology 2Good liquid, bad liquid 2CSC Awarded Department of Defense Biometrics Contract 2
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
... is especially formulated for non-denaturing polyacrylamide and ... gel loading solution contains a bromophenol blue ... and facilitate sample loading. EDTA has been ... cations and SDS has been added to ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
... Description: 100 g ... 70 kDa YAP from Human/mouse/rat samples. ... Research Focus: ... -20C Shipping ...
Biology Products: